清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study

医学 三叉神经痛 安慰剂 双盲 概念证明 麻醉 物理疗法 替代医学 计算机科学 操作系统 病理
作者
Anne Sofie Schott Andersen,Stine Maarbjerg,Navid Noory,Tone Bruvik Heinskou,Julie Lyng Forman,G. Cruccu,Messoud Ashina,Lars Bendtsen
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:21 (11): 994-1003 被引量:47
标识
DOI:10.1016/s1474-4422(22)00294-0
摘要

Trigeminal neuralgia is a severe facial pain disorder that is difficult to treat. Erenumab, a monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor, has proven efficacy in migraine. Erenumab modulates sensory processing in peripheral trigeminal pain pathways in mice and was reported to be effective for patients with trigeminal neuralgia in open-label studies. We aimed to evaluate the efficacy of erenumab in patients with trigeminal neuralgia.We did a randomised, double-blind, placebo-controlled trial in adults (aged 18-85 years) with idiopathic or classic trigeminal neuralgia as defined by the 3rd edition of the International Classification of Headache Disorders. The trial was based at the Danish Headache Center, Copenhagen University Hospital. Eligible participants had no clinically significant cerebrovascular or cardiovascular disease, had self-reported pain intensity of at least 4 on the 11-point Numeric Rating Scale (0=no pain, 10=worst pain imaginable), and had at least three daily pain paroxysms. After a 1-week pre-screening period, patients entered a 4-week baseline period. Participants who met pain inclusion criteria at the end of the baseline period were randomly assigned (1:1) to receive subcutaneous injections of either erenumab 140 mg or placebo and entered the 4-week follow-up period. Randomisation was done in blocks of 10 using a computer-generated schedule by a third-party company. Participants and assessors were masked to treatment allocation, and erenumab and placebo were packed in identical prefilled syringes. The primary outcome was the number of responders, defined as patients who had a reduction of at least 30% in mean average daily pain intensity during the follow-up period compared with during the baseline period, analysed in the intention-to-treat population. This trial is registered with the European Union Drug Regulating Authorities Clinical Trials Database, EudraCT number 2019-000848-95.We assessed 860 patients for suitability and excluded 741 between Oct 28, 2019, and Sept 13, 2021. 119 participants entered a 1-week pre-screening period and 26 were excluded, 93 participants entered a 4-week baseline period with 13 excluded before randomisation, and 80 participants were randomly assigned to erenumab 140 mg (n=40) or placebo (n=40). There was no difference between groups in the number of responders at 4 weeks in the intention-to-treat population (14 [35%] of 40 with erenumab vs 18 [45%] of 40 with placebo; estimated effect size -10% [95% CI -31 to 11]; p=0·36). 20 (50%) of 40 participants reported adverse events in each group. The most common adverse events were constipation (28%) and headache (10%) in the erenumab group, and headache (13%), constipation (10%), and abdominal pain (10%) in the placebo group.Erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia and CGRP probably does not have an important role in paroxysmal pain. Well tolerated, effective treatments in trigeminal neuralgia are still needed.Novartis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
深情安青的应助被xiaoju采纳,获得10
3秒前
帆帆帆完成签到 ,获得积分10
10秒前
lihongyan完成签到 ,获得积分10
10秒前
13秒前
hover完成签到,获得积分10
16秒前
Yuna完成签到,获得积分20
17秒前
xiaoju发布了新的文献求助10
17秒前
chemlink完成签到 ,获得积分10
19秒前
19秒前
嘿嘿完成签到 ,获得积分10
20秒前
lamb完成签到 ,获得积分10
20秒前
yuanmeng434完成签到 ,获得积分10
21秒前
wei发布了新的文献求助10
22秒前
Yuna发布了新的文献求助10
23秒前
清爽水之完成签到,获得积分10
29秒前
贪玩鸣凤完成签到,获得积分10
50秒前
哈哈哈哈完成签到 ,获得积分10
52秒前
孝顺的丹烟完成签到,获得积分10
1分钟前
1分钟前
王誉霖发布了新的文献求助10
1分钟前
1分钟前
楚楚完成签到 ,获得积分10
1分钟前
1分钟前
王誉霖完成签到,获得积分10
1分钟前
大方定帮完成签到,获得积分10
1分钟前
合适乐巧完成签到 ,获得积分10
1分钟前
缓慢凛完成签到,获得积分10
1分钟前
ghost完成签到 ,获得积分10
1分钟前
稳重傲柔完成签到,获得积分10
1分钟前
万能图书馆的应助被边疆采纳,获得10
1分钟前
温柔的海秋完成签到,获得积分10
1分钟前
2分钟前
任性的千筹完成签到,获得积分10
2分钟前
边疆发布了新的文献求助10
2分钟前
单薄飞双完成签到,获得积分10
2分钟前
Jzhaoc580完成签到 ,获得积分10
2分钟前
边疆完成签到,获得积分10
2分钟前
2分钟前
麦子发布了新的文献求助10
2分钟前
李木禾完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166463
求助须知:如何正确求助?哪些是违规求助? 9559494
关于积分的说明 21750516
捐赠科研通 7757246
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553507
邀请新用户注册赠送积分活动 2473845